

Special Issue

Novel Therapeutic Targets and Drug Development in Retinal Diseases

Message from the Guest Editor

Many ocular diseases caused by endogenous or exogenous insults lead to photoreceptor cell death, the ultimate cause of vision loss in various retinal diseases, which are currently not properly treated despite the increasing prevalence. The light-sensitive photoreceptor cells are terminally differentiated neurons that are not regenerated after degeneration or injury in adult mammals. The high heterogeneity of factors inducing photoreceptor degeneration hampers the development of effective therapeutic interventions. Several cellular and biochemical processes can contribute to photoreceptor death, including endoplasmic reticulum stress and unfolded protein response, oxidative stress, and inflammation, offering a vast repertoire of potential therapeutic targets. This Special Issue entitled “Novel Therapeutic Targets and Drug Development in Retinal Diseases” will contribute to understanding disease mechanisms better, opening novel avenues for targeting photoreceptor degeneration and accelerating the development and characterization of compounds for preclinical studies as a starting point for advanced drug development.

Guest Editor

Dr. Blanca Arango-Gonzalez

Institute for Ophthalmic Research, Department for Ophthalmology,
Eberhard Karls University of Tübingen, 72076 Tübingen, Germany

Deadline for manuscript submissions

closed (10 June 2023)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/109289

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceuticals and biopharmaceuticals. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).